Given the effects of LCRF‐0006 on EC monolayer integrity and vascular permeability in vitro, we then postulated that LCRF‐0006 may increase vascular permeability in tumors and enhance tumor response to anti‐cancer agents in vivo, in line with previous findings using ADH‐1.21 This evidence concerns the gene ADH1A and cancer.